Address: Dantestraat 75 1070 Brussel, Belgium
Tel: (+32) (0)2 525 82 11
Web: http://www.roche.be/portal/roche_be_fr_V2/copy_index
For over 100 years, we at Roche offer drugs and diagnostic solutions that allow patients the opportunity for a better and longer life. Our challenge is to find answers to unsolved medical needs while striving for academic excellence of the early detection and prevention of diseases to the diagnosis, treatment and its control. Roche thereby fulfills a pioneer in the field of personalized health care and supplies products that are adapted to the needs of a specific group of patients.
Roche is based in Basel, Switzerland. The two main divisions of the Group are both represented in Belgium, namely Roche Diagnostics Belgium in Brussels and Roche (Pharmaceuticals) in Anderlecht. The Roche Group employs 80,000 employees and markets its products on the market in more than 150 countries.
As an innovator in medicinal products and service related to the early detection, prevention, diagnosis and treatment of diseases, Roche is active on many fronts in order to improve the health and quality of life of people. Roche is active in Medicines, Diagnostic solutions and services, Products for research and Diabetes control.
Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here
